Telomir Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

TELO$0.69-2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		TELOMIR PHARMACEUTICALS, INC.
Date: March 28, 2024	By:	/S/ Chris Chapman
	Name:	Chris Chapman
	Title:	Chief Executive Officer
		(Principal Executive Officer)

By:	/S/ Nathen Fuentes
Name:	Nathen Fuentes
Title:	Chief Financial Officer
	(Principal Financial Officer)

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Dr. Craig Eagle
Person	Capacity	Date
/s/ Christopher Chapman	Chief Executive Officer and Chairman	March 28, 2024
Christopher Chapman	(Principal Executive Officer)
/s/ Nathen Fuentes, CPA	Chief Financial Officer	March 28, 2024
Nathen Fuentes, CPA	(Principal Financial Officer and Principal Accounting Officer)
/s/ Dr. Craig Eagle	Director	March 28, 2024
/s/ Christos Nicholoudis, Esq.	General Counsel and Director	March 28, 2024
Christos Nicholoudis, Esq.
/s/ Michael Jerman, CPA	Director	March 28, 2024
Michael Jerman, CPA
/s/ Brad Kroenig	Director	March 28, 2024
Brad Kroenig
/s/ Talhia Tuck	Director	March 28, 2024
Talhia Tuck
/s/ Hugh McColl III	Director	March 28, 2024
Hugh McColl III

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.